Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- PD-1, TIM-3, CTLA4 on CD4/CD8 lymphocytes
Study Overview
Brief Summary
Postoperative pneumonia is one of the most common complications after lung cancer surgery and associated with a morbidity and mortality. Postoperative lymphopenia has been recently identified as one of risk factors for postoperative pneumonia. According to recent studies in polytrauma, cancer or septic shock, T cells dysfunction may be related to high expression of inhibitory receptors on lymphocytes.
Detailed Description
This study will investigate prospectively TIM-3, PD-1 and CTLA4 expression on lymphocytes T cells before and after lung cancer surgery. Patients ≥ 18 years with no history of immunosuppressive state will be included.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient ≥ 18 years undergoing lung cancer surgery by thoracoscopy
Exclusion Criteria
- •Patient under guardianship/curatorship
- •Patient who received of radiotherapy or chemotherapy in the last 6 months
- •Patient under immunosuppressive treatment or dose of corticoids over 10 mg/day prednisolone or equivalent
- •Patient with history of malignant blood disease or auto-immune disease
- •Patient suffering from HIV infection and
- •Patients with pre-operative infection
- •Patient with an empiric antibiotic therapy introduced at operating room
Arms & Interventions
Patients undergoing lung cancer surgery
Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
Intervention: Blood samples (Biological)
Outcomes
Primary Outcomes
PD-1, TIM-3, CTLA4 on CD4/CD8 lymphocytes
Time Frame: Days 0, 1, 3
Correlation between expression of PD-1, TIM-3, CTLA4 on CD4/CD8 lymphocytes and the occurrence of lymphopenia. Measured by blood sample before lung cancer surgery, the next day lung cancer surgery and 3 days after lung cancer surgery. Analyzed by multicolour immunolabelling in flow cytometry
Secondary Outcomes
- functionality of CD4/CD8 lymphocytes and production of IF gamma, TNF and IL-2(Days 0, 1, 3)
- pneumonia(Days 3)